A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Lung, Ovarian, or Gastrointestinal/Colorectal Cancer.

Trial Profile

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Lung, Ovarian, or Gastrointestinal/Colorectal Cancer.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 05 Jan 2018 Planned End Date changed from 23 Jan 2022 to 17 Jun 2022.
    • 05 Jan 2018 Planned primary completion date changed from 24 Dec 2021 to 17 Jun 2022.
    • 05 Jan 2018 Planned initiation date changed from 6 Aug 2018 to 28 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top